A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:2
|
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [1] Congenital and immune-mediated thrombotic thrombocytopenic purpura
    Hovinga, J. A. Kremer
    HAEMOPHILIA, 2018, 24 : 17 - 17
  • [2] Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
    Adeyemi, Ayoade
    Razakariasa, Francesca
    Chiorean, Alexandra
    Sousa, Rui de Passos
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (06)
  • [3] Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura
    Aggarwal, Asha
    White, Danielle
    Pavord, Sue
    Thomas, Will
    Desborough, Michael J. R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (02) : 429 - 433
  • [4] IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA WITHOUT THROMBOCYTOPENIA
    Ul Abedin, Muhammad Shan
    Batool, Izza
    CHEST, 2024, 166 (04) : 2929A - 2930A
  • [5] Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura
    Comparon, Celine
    Galicier, Lionel
    Rebibou, Jean Michel
    Coppo, Paul
    Benhamou, Ygal
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (02) : 157 - 160
  • [6] Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura
    Li, Ang
    Hovinga, Johanna A. Kremer
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 82 - 84
  • [7] Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura
    Poullin, P.
    Bornet, C.
    Veyradier, A.
    Coppo, P.
    DRUGS OF TODAY, 2019, 55 (06) : 367 - 376
  • [8] Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura
    Ozpolat, Hasan Tahsin
    Stolla, Moritz
    BLOOD TRANSFUSION, 2023, 21 (05) : 369 - 374
  • [9] Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults
    Blennerhassett, Richard
    Curnow, Jennifer
    Pasalic, Leonardo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2020, 46 (03): : 289 - 301